Absorption of montelukast is transporter mediated: A common variant of OATP2B1 is associated with reduced plasma concentrations and poor response

Pharmacogenetics and Genomics

Volumn 19, Issue 2, 2009, Pages 129-138

  Mougey, Edward B ^a   Feng, Hua ^b   Castro, Mario ^c,e   Irvin, Charles G ^d,e   Lima, John J ^a,e  

^a NEMOURS CHILDREN S CLINIC   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e American Lung Association   (United States)

Author keywords

Asthma; Human OATP2B1 protein; Intestinal absorption; Leukotriene antagonists; Membrane transport proteins; Montelukast; Pharmacodynamics; Pharmacokinetics; Single nucleotide polymorphism

Indexed keywords

BROMSULFOPHTHALEIN; CARRIER PROTEIN; CHOLIC ACID; CITRUS FRUIT EXTRACT; ESTRONE SULFATE; FOLIC ACID; MONTELUKAST; PRAVASTATIN; TAUROCHOLIC ACID; VERAPAMIL; VERLUKAST;

ANIMAL CELL; ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG UPTAKE; GENE; GENETIC PROCEDURES; GENETIC VARIABILITY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MICHAELIS MENTEN KINETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1A2 GENE; SLCO2B1 GENE;

ABSORPTION; ACETATES; ADULT; CACO-2 CELLS; GENETIC VARIATION; GENOTYPE; HUMANS; ORGANIC ANION TRANSPORTERS; PHENOTYPE; QUINOLINES;

CITRUS;

EID: 59549106159     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32831bd98c     Document Type: Article

References (53)

1. Jones TR, Labelle M, Belley M, Champion E, Charette L, Evans J, et al. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 1995; 73:191-201.
2. Drazen JM. Asthma therapy with agents preventing leukotriene synthesis or action. Proc Assoc Am Physicians 1999; 111:547-559.
3. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 2004; 173:1503-1510.
4. Blake KV. Montelukast: data from clinical trials in the management of asthma. Ann Pharmacother 1999; 33:1299-1314.
5. Jarvis B, Markham A. Montelukast: a review of its therapeutic potential in persistent asthma. Drugs 2000; 59:891-928.
6. Muijsers RB, Noble S. Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age. Paediatr Drugs 2002; 4:123-139.
7. Lima JJ. Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. Mol Diagn Ther 2007; 11:97-104.
8. Weiss ST, Litonjua AA, Lange C, Lazarus R, Liggett SB, Bleecker ER, et al. Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J 2006; 6:311-326.
9. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000; 56:1054-1070.
10. Asano K, Shiomi T, Hasegawa N, Nakamura H, Kudo H, Matsuzaki T, et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002; 12:565-570.
11. Klotsman M, York TP, Pillai SG, Vargas-Irwin C, Sharma SS, van den Oord EJ, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 2007; 17:189-196.
12. Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate ST, Holloway JW, et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55 (Suppl 2):S28-S31.
13. Whelan GJ, Blake K, Kissoon N, Duckworth LJ, Wang J, Sylvester JE, et al. Effect of montelukast on time-course of exhaled nitric oxide in asthma: influence of LTC4 synthase A(-444)C polymorphism. Pediatr Pulmonol 2003; 36:413-420.
14. Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2006; 173:379-385.
15. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46:3-26.
16. 4 receptor antagonist, MK-0476. Int J Pharm 1996; 134:59-70.
17. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001; 46:27-43.
18. Zhao JJ, Rogers JD, Holland SD, Larson P, Amin RD, Haesen R, et al. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos 1997; 18:769-777.
19. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/SLCO super-family, new nomenclature and molecular/functional properties. Pflugers Arch 2004; 447:653-665.
20. Artursson P. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci 1990; 79:476-482.
21. Kopplow K, Letschert K, Konig J, Walter B, Keppler D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol 2005; 68:1031-1038.
22. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999; 55:929-937.
23. Youdim KA, Avdeef A, Abbott NJ. In vitro trans-monolayer permeability calculations: often forgotten assumptions. Drug Discov Today 2003; 8:997-1003.
24. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989; 96:736-749.
25. Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest 1998; 114:998-1007.
26. ALA-ACRC. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007; 175:235-242.
27. Amin RD, Cheng H, Rogers JD. Determination of MK-0476 in human plasma by liquid chromatography. J Pharm Biomed Anal 1995; 13:155-158.
28. Bennett CD, Campbell MN, Cook CJ, Eyre DJ, Nay LM, Nielsen DR, et al. The Light Typer: high-throughput genotyping using fluorescent melting curve analysis. Biotechniques 2003; 34:1288-1295.
29. Glantz SA. Primer of Biostatistics. 6th ed. New York, NY: McGraw-Hill Medical Pub; 2005.
30. Oehlert GW. A first course in design and analysis of experiments. 1st ed. New York, NY: W.H. Freeman; 2000.
31. Rao PV. Statistical research methods in the life sciences. 1st ed. Pacific Grove, CA: Duxbury Press; 1998.
32. Hofer M. Transport Across Biological Membranes. Marshfield, Mass: Pitman Publishing, INC.; 1981.
33. Nishimura T, Kubo Y, Kato Y, Sai Y, Ogihara T, Tsuji A. Characterization of the uptake mechanism for a novel loop diuretic, M17055, in Caco-2 cells: involvement of organic anion transporting polypeptide (OATP)-B. Pharm Res 2007; 24:90-98.
34. Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kalo Y, Tamai I, et al. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab Dispos 2006; 34:1423-1431.
35. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001; 120:525-533.
36. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 2004; 308:438-445.
37. Yamaguchi H, Okada M, Akitaya S, Ohara H, Mikkaichi T, Ishikawa H, et al. Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res 2006; 47:1196-1202.
38. Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 2007; 81:495-502.
39. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, et al. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2005; 33:518-523.
40. Grube M, Kock K, Karner S, Reuther S, Ritter CA, Jedlitschky G, et al. Modification of OATP2B1-mediated transport by steroid hormones. Mol Pharmacol 2006; 70:1735-1741.
41. Letschert K, Faulstich H, Keller D, Keppler D. Molecular Characterization and Inhibition of Amanitin Uptake into Human Hepatocytes. Toxicol Sci 2006; 91:140-149.
42. Landowski CP, Anderle P, Sun D, Sadee W, Amidon GL. Transporter and ion channel gene expression after Caco-2 cell differentiation using 2 different microarray technologies. AAPS J 2004; 6:e21.
43. Nielsen M, Bressendorff S, Møller J, Olsen J. Troelsen JT. Mapping of HNF4a binding sites, acetylation of histone H3 and expression in Caco2 cells. [GSE7745]. National Center for Biotechnology Information. Geo Datasets 2008.
44. Expert Panel Report 3 (EPR-3). Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007; 120:394-3138.
45. Peters SP, Jones CA, Haselkorn T, Mink DR, Valacer DJ, Weiss ST. Real-world evaluation of asthma control and treatment (REACT): findings from a national Web-based survey. J Allergy Clin Immunol 2007; 119:1454-1461.
46. Maubon N, Le Vee M, Fossati L, Audry M, Le Ferrec E, Bolze S, et al. Analysis of drug transporter expression in human intestinal Caco-2 cells by real-time PCR. Fundam Clin Pharmacol 2007; 21: 659-663.
47. Sambuy Y, de Angelis I, Ranaldi G, Scarino ML, Stammati A, Zucco F. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol 2005; 21:1-26.
48. Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 2006; 80:607-620.
49. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 2003; 306:703-708.
50. ALA-ACRC. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl J Med 2001; 345:1529-1536.
51. Peters SP, Anthonisen N, Castro M, Holbrook JT, Irvin CG, Smith LJ, et al. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007; 356:2027-2039.
52. Long AD, Langley CH. The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits. Genome Res 1999; 9:720-731.
53. Freedman ML, Reich D, Penney KL, McDonald GJ, Mignault AA, Patterson N, et al. Assessing the impact of population stratification on genetic association studies. Nat Genet 2004; 36:388-393.